Quarterly ResultApr 30, 2026, 06:52 AM
CAH Q3 Revenue +11% to $60.9B; Non-GAAP EPS +35% to $3.17; Raises FY26 Outlook
AI Summary
Cardinal Health reported strong third-quarter fiscal year 2026 results, with revenue increasing 11% to $60.9 billion and non-GAAP diluted EPS rising 35% to $3.17. Despite a GAAP operating earnings decrease due to a goodwill impairment, the company raised and narrowed its fiscal year 2026 non-GAAP EPS guidance to $10.70-$10.80. The company also reduced debt and completed an additional $250 million in share repurchases, bringing the fiscal year total to $1.0 billion. This performance was driven by strong operating results, particularly in Pharmaceutical and Specialty Solutions.
Key Highlights
- Q3 FY26 Revenue increased 11% to $60.9 billion.
- Non-GAAP diluted EPS increased 35% to $3.17.
- GAAP diluted EPS decreased 20% to $1.69, impacted by $184 million goodwill impairment.
- Raised and narrowed FY26 non-GAAP EPS guidance to $10.70-$10.80.
- Completed additional $250 million share repurchase, totaling $1.0 billion for FY26.
- Pharmaceutical and Specialty Solutions segment profit increased 18% to $784 million.
- Adjusted free cash flow guidance raised to $3.3 billion to $3.7 billion.
- Reduced debt and lowered leverage ratio to 3.0X.